XML 96 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Feb. 28, 2017
USD ($)
item
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
USD ($)
item
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
License agreements                              
Long term investments                         $ 133,657 $ 99,199  
Research and development expense                         1,154,111 1,197,957 $ 1,326,134
Unrealized gain (loss) on long term investments                         34,458 (44,093) (24,275)
Current assets                         2,481,488 1,832,254  
Current liabilities                         $ 513,340 425,277  
Agenus                              
License agreements                              
Number of program targets | item         4 3   4              
Royalty payments on future global net sales (as a percent)                         15.00%    
Research and development expense                         $ 1,500 4,600 19,500
Noncurrent assets                 $ 67,600   $ 67,600        
Agenus | Accrued and other liabilities                              
License agreements                              
Accrued and other liabilities                         $ 1,600 2,300  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                         6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                              
License agreements                              
Royalty payments on future global net sales (as a percent)                         12.00%    
Additional milestone payments under the license agreement         $ 510,000                    
Agenus | Development Milestones                              
License agreements                              
Upfront payment under license agreement     $ 5,000 $ 5,000                     20,000
Agenus                              
License agreements                              
Total consideration paid               $ 60,000              
Long term investments                         $ 72,300 42,300  
Shares owned following stock purchase (as a percent)         11.00%   9.00%                
Ownership percentage (as a percent)                         13.00%    
Unrealized gain (loss) on long term investments                         $ 30,000 (15,600) (13,600)
Total revenues                 19,900 $ 12,800 115,500 $ 30,300      
Net income (loss)                 (46,300) $ (33,700) (80,700) $ (113,200)      
Current assets                 107,200   107,200     74,800  
Noncurrent assets                           61,600  
Current liabilities                 132,900   132,900     68,100  
Noncurrent liabilities                 $ 219,800   $ 219,800     $ 203,000  
Agenus | Stock purchase agreement                              
License agreements                              
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                          
Purchase price of common stock   $ 60,000                          
Per share price | $ / shares $ 4.40 $ 6.00                          
Discount for lack of marketability $ 4,500                            
Fair value of shares on the issuance date 39,500                            
Total consideration paid $ 60,000                            
Long term investments                             39,500
Research and development expense                             $ 20,500